JP7012658B2 - アミロイドβタンパク質の排出を刺激する組成物及び方法 - Google Patents

アミロイドβタンパク質の排出を刺激する組成物及び方法 Download PDF

Info

Publication number
JP7012658B2
JP7012658B2 JP2018549168A JP2018549168A JP7012658B2 JP 7012658 B2 JP7012658 B2 JP 7012658B2 JP 2018549168 A JP2018549168 A JP 2018549168A JP 2018549168 A JP2018549168 A JP 2018549168A JP 7012658 B2 JP7012658 B2 JP 7012658B2
Authority
JP
Japan
Prior art keywords
composition
amyloid
uptake
gfb
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018549168A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019512507A5 (enExample
JP2019512507A (ja
Inventor
カリパダ パハン
アルナヴァ ゴーシュ
Original Assignee
ラッシュ ユニヴァーシティ メディカル センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラッシュ ユニヴァーシティ メディカル センター filed Critical ラッシュ ユニヴァーシティ メディカル センター
Publication of JP2019512507A publication Critical patent/JP2019512507A/ja
Publication of JP2019512507A5 publication Critical patent/JP2019512507A5/ja
Application granted granted Critical
Publication of JP7012658B2 publication Critical patent/JP7012658B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2018549168A 2016-03-15 2017-03-10 アミロイドβタンパク質の排出を刺激する組成物及び方法 Active JP7012658B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662308374P 2016-03-15 2016-03-15
US62/308,374 2016-03-15
PCT/US2017/021799 WO2017160629A1 (en) 2016-03-15 2017-03-10 COMPOSITION AND METHODS FOR STIMULATING CLEARANCE OF AMYLOID-β PROTEIN

Publications (3)

Publication Number Publication Date
JP2019512507A JP2019512507A (ja) 2019-05-16
JP2019512507A5 JP2019512507A5 (enExample) 2020-04-23
JP7012658B2 true JP7012658B2 (ja) 2022-02-14

Family

ID=59852353

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018549168A Active JP7012658B2 (ja) 2016-03-15 2017-03-10 アミロイドβタンパク質の排出を刺激する組成物及び方法

Country Status (5)

Country Link
US (2) US11135180B2 (enExample)
EP (1) EP3429671B1 (enExample)
JP (1) JP7012658B2 (enExample)
CA (1) CA3017760A1 (enExample)
WO (1) WO2017160629A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111084768A (zh) * 2018-10-24 2020-05-01 中国科学院昆明动物研究所 吉非罗齐及其衍生物用于治疗和/或预防神经退行性疾病的用途
JP2022541021A (ja) * 2019-07-16 2022-09-21 ラッシュ・ユニバーシティ・メディカル・センター 神経変性障害を治療するためのベンゾエート含有組成物の使用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150313863A1 (en) 2012-12-07 2015-11-05 Rush University Medical Center Composition and Method for Treating Neuronal Ceroid Lipofuscinosis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1392287B8 (en) * 2001-05-25 2007-01-10 Schering Corporation Use of substituted azetidinone derivatives in the treatment of Alzheimer's disease
US20050031651A1 (en) * 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US20150320706A1 (en) * 2014-05-12 2015-11-12 Chiesi Farmaceutici S.P.A. Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy
WO2016201086A1 (en) * 2015-06-12 2016-12-15 Rush University Medical Center Compositions and methods for stimulating adam10-mediated nonamyloidogenic proteolysis of amyloid precursor protein

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150313863A1 (en) 2012-12-07 2015-11-05 Rush University Medical Center Composition and Method for Treating Neuronal Ceroid Lipofuscinosis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
The Journal of Biological Chemistry，2015年，Vol.290, No.16，pp.10309-10324
The Journal of Neuroscience，2014年，Vol.34, No.29，pp.9607-9620

Also Published As

Publication number Publication date
WO2017160629A1 (en) 2017-09-21
US11135180B2 (en) 2021-10-05
EP3429671B1 (en) 2024-05-01
CA3017760A1 (en) 2017-09-21
US20210401772A1 (en) 2021-12-30
EP3429671A1 (en) 2019-01-23
JP2019512507A (ja) 2019-05-16
EP3429671A4 (en) 2019-10-16
US20200297657A1 (en) 2020-09-24
US11844767B2 (en) 2023-12-19

Similar Documents

Publication Publication Date Title
Kim et al. AIM2 inflammasome contributes to brain injury and chronic post-stroke cognitive impairment in mice
US11351142B2 (en) Composition and method for treating neuronal ceroid lipofuscinosis
Guo et al. Up-regulation of miR-122 protects against neuronal cell death in ischemic stroke through the heat shock protein 70-dependent NF-κB pathway by targeting FOXO3
Martínez-Levy et al. Increased expression of BDNF transcript with exon VI in hippocampi of patients with pharmaco-resistant temporal lobe epilepsy
US10844380B1 (en) Uses for prevention or treatment of brain diseases using microrna
JP2017536363A (ja) リソソーム蓄積症治療のための組成物及び方法
US20180217163A1 (en) Treatment of neurodegenerative conditions using pkc activators after determining the presence of the apoe4 allele
EP3233073A1 (en) Compound for treatment of myotonic dystrophy type 1
Wang et al. A new gentiopicroside derivative improves cognitive deficits of AD mice via activation of Wnt signaling pathway and regulation of gut microbiota homeostasis
EP3638277B1 (en) Compositions and methods for beta secretase inhibition
JP7012658B2 (ja) アミロイドβタンパク質の排出を刺激する組成物及び方法
Carbone et al. Suppression of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced nitric-oxide synthase 2 expression in astrocytes by a novel diindolylmethane analog protects striatal neurons against apoptosis
JP6928450B2 (ja) エンドセリンｂ受容体アゴニストを用いた、神経精神疾患を治療するための組成物及び方法
Carbone et al. Nuclear factor kappa-B mediates selective induction of neuronal nitric oxide synthase in astrocytes during low-level inflammatory stimulation with MPTP
JP2008531710A (ja) 神経変性疾患の調節
JP2016516201A (ja) 神経保護性ｐｋｃ活性化因子を特定する方法
Shao et al. miR-135b: An emerging player in cardio-cerebrovascular diseases
Song et al. Increased expression of Rho-associated protein kinase 2 confers astroglial Stat3 pathway activation during epileptogenesis
Wang et al. Cyclooxygenase-1 deletion in 5× FAD mice protects against microglia-induced neuroinflammation and mitigates cognitive impairment
WO2016201086A1 (en) Compositions and methods for stimulating adam10-mediated nonamyloidogenic proteolysis of amyloid precursor protein
CN111603561A (zh) microRNA-425及其类似物作为阿尔茨海默病治疗的核苷酸药物的应用
WO2023133414A2 (en) Selective elimination of senescent cells by ferroptosis induction
WO2025240566A1 (en) Small molecule steroid receptor coactivator stimulators for use in repairing tissue
Su et al. PCSK9 exacerbates sevoflurane-induced neuroinflammatory response and apoptosis by up-regulating cGAS-STING signal
Koh et al. Reducing miR485-3p ameliorates Alzheimers disease pathology by regulation of amyloid beta and neuro-inflammation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200309

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200309

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210521

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211124

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211220

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220118

R150 Certificate of patent or registration of utility model

Ref document number: 7012658

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250